5Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibioticresistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother, 1999,43 : 1379-1382.
6Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect ,2005,11 ( Suppl 4 ) : 17-32.
7Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis, 2002,34:634-640.
8Chamot E, Boffi El Amari E, Rohner P, et al. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother, 2003,47 : 2756 -2764.
9American Thoracic Society ; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med,2005,171:388-416.
8Clinical and I.aboratory Standards Institute(CLSI). Perform ance standards for Antimicrobial susceptibility testing[S]. M100-S17, 2007.
9Clinical and Laboratory Standards Institute (CLSI). Perform anee standards for Antimicrobial susceptibility testing [S]. M100-S19,2009.
10Bratu S, I.andman D, Haag R, et al. Rapid spread of carbapenem resistant Klebsiella pneumoniae in New York City: anew threat to our antibiotic armamentarium[J]. Arch Int Meal.2005,165(12) :1430-1435.
3Craven DE,Steger KA.Ventilator associated bacterial pneumonia;challenges in diagnosis,treatment and prevention[J].New Horiz,1998,6:S30-45.
4CLSI Performance standards for antimicrobial susceptibility testing[S]. Twenty second Informational supplement, M 100-$222012.32(3).
5Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing Aminoglyeoside Therapy for Nosocornial Pneumonia Caused by Gram-Negative Bacteria [J]. Antimierob Agents Chemother, See comment in PubMed Commonsb, 1999, 43(3): 623-629.
6Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of AmericaJAmerican Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults[J]. Clin Infect Dis, 2007, 44 (Suppl 2): $27-72.
7Mohr JF, Jones A, Ostrosky-Zeichner L, et al. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonase aruginosa in a private, university-affiliated teaching hospital: an 8-year-experience 1995-2002 [J]. Antimicrob Agents, 2004, 24 (4): 346-351.
8Park SY, Park HJ, Moon SM, et al. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia[J]. BMC Infect Dis, 2012, 12(1): 308.
9Robert A, Bonomo RA, Szabo D. Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa[J]. Clin Infect Dis, 2006, 43(Supp12): $49-56.
10HassettDJ, KorthagenTR, Irvin RT, et al. Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies [J]. ExpertOpinTherTargets, 2010, 14 (2):117-130.
